Coca-Cola’s (NYSE: KO) bottom line and topline numbers in Q2 surpassed the consensus estimate. The beverage giant reported adjusted earnings of $0.63 per share, a tad higher than the expected earnings of $0.62 per share. Revenue rose 6% year-over-year to $10 billion and was higher than the predicted revenue of $9.79 billion.
Coca-Cola stock increased by 2% in the pre-market hours and traded close to the 52-week high mark it achieved during the last week.
Earnings, on a GAAP basis, grew 12% to $0.61 per share in the recently ended quarter. Non-GAAP EPS grew 4% to $0.63, which included the impact from a 9-point currency headwind. Organic revenue grew 6%.
For the full-year 2019, the Atlanta, Georgia-based company updated its revenue guidance. Coca-Cola now expects its organic revenue to grow 5% versus the previously estimated growth of about 4%. Comparable currency neutral net revenues (non-GAAP) are estimated to grow 12% compared to the prior growth range of 12-13%.
For comparable net revenues, the company expects 4% currency headwind in 2019 based on the current rates and including the impact of hedged positions compared to the previously guided range of 3-4%. 2019 non-GAAP EPS growth was maintained in the previously projected range of -1% to 1% growth versus $2.08 in 2018.
For Q3 comparable net revenues (non-GAAP), Coca-Cola sees 6% tailwind from acquisitions, divestitures, and structural items; 3% currency headwind based on the current rates and including the impact of hedged positions.
Earlier this month, rival beverage maker PepsiCo (NASDAQ: PEP) reported a 2% increase in revenues to $16.4 billion for its most recent quarter. Meanwhile, adjusted earnings dropped to $1.54 per share due to lower margins.
Shares of Coca-Cola have given a positive return of 8% so far this year and 13% in the past 12 months period.
BlackBerry Limited (NYSE: BB) is slated to report its fourth-quarter 2020 earnings results on Tuesday, March 31, after the market closes. The top line will be benefited by BlackBerry Cylance
The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone. As the world grapples with the outbreak, several
Altimmune Inc. (NASDAQ: ALT) reported its earnings results for fiscal-year 2019. Revenues totaled $5.8 million compared to $10.3 million last year. The drop in revenues was caused by lower billings